Generated by AI
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, or off-the-shelf, cell therapies for serious medical conditions. Its current programs center on cell replacement therapies for ophthalmology, neurology, hearing loss, and corneal disease, with product candidates designed to restore or replace damaged cells in targeted tissues. The company’s pipeline includes OpRegen for retinal disorders, OPC1 for spinal cord injury, COR1 for corneal endothelial disease, and other platform-based programs supported by its proprietary manufacturing and delivery capabilities. Lineage Cell Therapeutics, Inc. works at the intersection of regenerative medicine and specialty therapeutics, addressing areas of high unmet medical need through pluripotent stem cell-based technologies.
Website2173 Salk Avenue
Carlsbad, CA, 92008
United States
The latest articles about LCTX.
Summary of Nov 18's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Summary of Feb 18's posts. Generated by AI.
Investors talking about LCTX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.